Compare RXT & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RXT | DRTS |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | United States | Israel |
| Employees | N/A | 121 |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2020 | N/A |
| Metric | RXT | DRTS |
|---|---|---|
| Price | $5.14 | $13.08 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $1.71 | ★ $8.67 |
| AVG Volume (30 Days) | ★ 14.1M | 643.8K |
| Earning Date | 05-07-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.13 | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $2,685,700,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.35 | $699.98 |
| P/E Ratio | $159.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.39 | $3.01 |
| 52 Week High | $8.60 | $14.11 |
| Indicator | RXT | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 52.47 |
| Support Level | N/A | $11.51 |
| Resistance Level | N/A | $14.00 |
| Average True Range (ATR) | 0.00 | 0.86 |
| MACD | 0.00 | -0.19 |
| Stochastic Oscillator | 0.00 | 43.88 |
Rackspace Technology Inc is an end-to-end, hybrid, multi-cloud technology services company. It designs, builds, and operates its customers' cloud environments across all technology platforms, irrespective of technology stack or deployment model. The company's solutions include Application Services, Data, Colocation, Cloud, Managed Hosting, Professional Services, and Security and Compliance. It has two reportable segments: Private Cloud and Public Cloud. Maximum revenue is generated from the Public Cloud segment, which offers cloud solutions through managed services, elastic engineering, and professional services offerings for customer environments hosted on the AWS, Microsoft Azure, and Google Cloud public cloud platforms. Geographically, the company derives its key revenue from the U.S.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.